On the stock market since 2020, it operates in the world of health and science. It has 6,300 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $753.1M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 56 buys and 13 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $104 — 15,270% above today’s price.
A loss of $58.3M against $753.1M in annual sales.
The stock sits at $0.68. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ATIP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ATIP has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.